European Archives - Page 484 of 1166 - European Medical Journal

Difficult-to-Treat: Treating Symptoms Not Numbers

Nebojsa Skrepnik joins Jonathan Sackier on this episode of the EMJ Podcast to discuss opening a clinical research centre and platelet-rich plasma treatments.

EMJ Nephrology 10 [Infographic 3] 2022

This infographic explores a contemporary strategy to decrease the risk of cardiovascular disease and mortality associated with end-stage kidney disease (ESKD).

EMJ

Infographic: Improving Outcomes in Haemodialysis: A New Look at an Old Issue

This infographic explores a contemporary strategy to decrease the risk of cardiovascular disease and mortality associated with end-stage kidney disease (ESKD).

Optimising Antimicrobial Stewardship to Tackle Clostridioides difficile Infection and Improve Patient Outcomes

Clostridioides difficile, formerly known as Clostridium difficile, is a Gram-positive spore-forming and toxin-producing bacterium that causes diarrhoea in vulnerable patient groups. It is a common hospital-acquired infection but also occurs in the community.

EMJ Microbiology & Infectious Diseases 3 [Supplement 2] 2022

Infectious disease experts Benoît Guery, Associate Professor of Infectious Diseases, University Hospital, Lausanne, Switzerland, and…

Precision Medicine in Prostate Cancer – Interview with Henrik Grönberg

Focusing on the topic of precision medicine in prostate cancer, this podcast offers valuable insights into the impact that its widespread…

New Frontiers in Chronic Obstructive Pulmonary Disease: Where Are We Heading?

All human diseases, including COPD, are the end result of gene–environment interactions.1 However, this conventional model is being modified. COVID-19 demonstrated that mortality is higher in older versus younger individuals. The viral and environmental exposures were the same, but the obvious difference was age.

EMJ Respiratory 10 [Supplement 1] 2022

All human diseases, including COPD, are the end result of gene–environment interactions. However, this conventional model is being modified. COVID-19 demonstrated that mortality is higher in older versus younger individuals. The viral and environmental exposures were the same, but the obvious difference was age.

Creating winning pharma communications

Silvia Taylor, Executive Vice President and Chief Communications Officer, Novavax, discusses her passion for engaging the world in the wonder of science.

Infographic: Systemic mastocytosis (SM) is a rare form of mast cell disorder characterised by abnormal proliferation and activation of mast cells

Systemic Mastocytosis Disease Awareness Infographic: Learn more about this rare disease, its prevelance, symptoms, sub-types and diagnosis.